Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmaron Beijing Co (OTCPK:PHBBF) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Pharmaron Beijing Co Forward PE Ratio Related Terms
Pharmaron Beijing Co Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Pharmaron Beijing Co's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmaron Beijing Co Forward PE Ratio Chart
Pharmaron Beijing Co Annual Data
Trend
2024-12
2025-12
Forward PE Ratio
13.31
11.16
Pharmaron Beijing Co Quarterly Data
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
13.31
13.88
13.69
11.35
11.16
10.90
PHBBF vs VRTX, REGN, RVMD: Forward PE Ratio Comparison
For the Biotechnology subindustry, Pharmaron Beijing Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmaron Beijing Co Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Pharmaron Beijing Co's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Pharmaron Beijing Co (PHBBF) has a Forward PE Ratio of 11.77 as of Jul. 30, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Pharmaron Beijing Co and its competitors. According to the industry distribution chart, Pharmaron Beijing Co ranks #222 out of 354 companies in the Biotechnology industry, placing it in the top 62.7%.
Is Pharmaron Beijing Co's Forward PE Ratio too high?
Pharmaron Beijing Co's current Forward PE Ratio is 11.77. The Biotechnology industry median Forward PE Ratio is 21.97. Pharmaron Beijing Co's value of 11.77 is 46.4% below this industry median. Based on the distribution chart, Pharmaron Beijing Co ranks #222 out of 354 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Pharmaron Beijing Co has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's Forward PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmaron Beijing Co ranks #222 out of 354 companies for Forward PE Ratio. This places Pharmaron Beijing Co in the lower half of its industry. The industry median Forward PE Ratio is 21.97. Pharmaron Beijing Co's value of 11.77 is 46.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 21.97, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmaron Beijing Co's current Forward PE Ratio of 11.77 is 46.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Pharmaron Beijing Co and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 21.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmaron Beijing Co's current Forward PE Ratio is 11.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Pharmaron Beijing Co (PHBBF) has a current Forward PE Ratio of 11.77. The stock's GF Value™ is $1.79, compared to a current price of $1.93 — trading 7.8% above its estimated fair value. The current Forward PE Ratio is 11.77 and 46.4% below the Biotechnology industry median of 21.97. Pharmaron Beijing Co's overall GF Score™ is 92/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Pharmaron Beijing Co (PHBBF), the current Forward PE Ratio is 11.77 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmaron Beijing Co (PHBBF) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued.
The current stock price of $1.93 is trading 7.8% above its estimated GF Value™ of $1.79.
Key valuation signals for PHBBF:
Forward PE Ratio: 11.77
GF Value™: $1.79 vs. price of $1.93 (7.8% above fair value)
Industry Position: 46.4% below the Biotechnology median (#222 of 354)
No single metric tells the full story. See the PHBBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
92GF Score
Get the complete analysis for PHBBF
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHBBF has been successfully added to your 
